MHRA guidance on the supply of unlicensed medicinal products (‘specials’) better known as MHRA Guidance Note 14 has been updated. This guidance
has been updated following the consolidation of medicines legislation into the Human Medicines Regulations 2012 and takes into account the outcomes of relevant European court cases.
This guidance note provides advice on the manufacture, importation, distribution and supply of unlicensed medicinal products for human use (commonly described as ‘specials’) which have been specially manufactured or imported to the order of a doctor, dentist, nurse independent prescriber, pharmacist independent prescriber or supplementary prescriber for the treatment of individual patients.
[read more…]
